IPP Bureau
Ind-Swift Laboratories receives certifications from Bureau Veritas
By IPP Bureau - November 24, 2025
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
FDA slaps gene therapy Elevidys with boxed warning after fatal liver failures
By IPP Bureau - November 24, 2025
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
FDA investigates fatal case linked to rare blood disorder drug Adzynma
By IPP Bureau - November 24, 2025
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
Moderna bags $1.5 billion 5-Yr loan to boost financial flexibility
By IPP Bureau - November 24, 2025
The non-dilutive financing includes three tranches
Bayer’s experimental stroke drug could reshape secondary stroke prevention
By IPP Bureau - November 24, 2025
Millions of stroke survivors across the world may soon have a new defense
Mesoblast teams with NIH to launch pivotal trial of life-saving cell therapy in adults with severe aGvHD
By IPP Bureau - November 24, 2025
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Alvotech and Advanz Pharma secure European nod for Gobivaz, first biosimilar to Simponi
By IPP Bureau - November 24, 2025
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Texas hits Sanofi, Bristol-Myers Squibb with lawsuit over blood thinner drug efficacy
By IPP Bureau - November 24, 2025
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
GSK's TESARO sues AnaptysBio over alleged breach of cancer drug licence deal
By IPP Bureau - November 24, 2025
Contineum MS drug stumbles in mid-stage trial
By IPP Bureau - November 24, 2025
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
BioNxt secures Eurasian patent for breakthrough sublingual MS therapy
By IPP Bureau - November 24, 2025
The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases
Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
By IPP Bureau - November 24, 2025
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Hester Biosciences appoints Ashish Desai as CFO
By IPP Bureau - November 23, 2025
Desai is currently serving the company as Group Finance Controller
Aayush Wellness partners with Blinkit to strengthen distribution network
By IPP Bureau - November 23, 2025
The partnership will enable rapid and reliable product delivery
Cosmo and Glenmark receives market authorization of Winlevi in Europe
By IPP Bureau - November 23, 2025
Winlevi is authorized in EU for the treatment of acne vulgaris
